Regeneron, Bayer's Eylea nabs six months of pediatric exclusivity as competition waits to enter the market

Regeneron and Bayer’s blockbuster eye drug Eylea has been given six months more protection from competition — now extending into the first half of 2024.

The FDA granted the blockbuster VEGF inhibitor pediatric exclusivity for the next six months on Friday — sending the timeline for biosimilar market entry to May 17, 2024. Exclusivity for Regeneron’s injection was supposed to run out in late 2023.